{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/pityriasis-rosea/","result":{"data":{"firstChapter":{"id":"82c04d82-7b6f-594a-8190-44f70c341f1b","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 6497af8a-783b-4fb9-85d1-4eb0db2ca83f --><h1>Pityriasis rosea: Summary</h1><!-- end field 6497af8a-783b-4fb9-85d1-4eb0db2ca83f -->","htmlStringContent":"<!-- begin item 63e08b77-43da-4a24-b50b-8d267c026301 --><!-- begin field c84ffda9-73fa-424f-addd-48271d9a06d7 --><ul><li>Pityriasis rosea is a self-limiting skin rash characterized by distinctive, scaly, erythematous lesions and, in some people, a herald patch that typically appears 5–15 days before the more generalized rash.<ul><li>It mainly affects older children and young adults (commonly between 10 and 35 years of age), and is more common in women than in men.</li></ul></li><li>In most people pityriasis rosea resolves completely without long-term complications.<ul><li>Pityriasis rosea in the first 15 weeks of pregnancy has been associated with adverse outcomes including miscarriage and premature delivery.</li></ul></li><li>Diagnosis is clinical, based on the appearance and distribution of the lesions:<ul><li>Pityriasis rosea typically starts with a 'herald patch' that appears before the generalized eruption — this may not always be present. The herald patch is usually larger than subsequent lesions (typically 2–5 cm in diameter) and most often develops on the trunk, thigh, upper arm, or neck, but can appear anywhere on the body.</li><li>Discrete lesions are pink-red (salmon coloured) or fawn coloured, flat or slightly raised, circular or oval, typically 0.5–1 cm in diameter, and usually slightly scaly (scaling is typically confined to the edge of the lesion with central clearance).</li><li>Distribution of lesions is usually symmetrical. Most occur on the trunk (forming a 'Christmas tree' pattern on the upper back and a V-shape on the upper chest) and proximal limbs, with few distal to the mid-upper arm and mid-thigh.</li></ul></li><li>If pityriasis rosea develops in pregnancy — management should be discussed urgently with secondary care.</li><li>For most people with pityriasis rosea, no treatment is required. The rash may worsen before it resolves, with new crops of lesions continuing to appear for up to 6 weeks. It will usually settle without treatment within 2–3 months, but may take up to 5 months to disappear.<ul><li>After the rash has disappeared, there may be some hyperpigmentation or hypopigmentation of the affected skin for several months, but there should be no scarring.</li></ul></li><li>For people with itch, an emollient or a mild or moderately-potent topical corticosteroid (depending on the severity of itch) may provide symptomatic relief. A sedating oral antihistamine may be considered at night if itching affects sleep (off-label).</li></ul><!-- end field c84ffda9-73fa-424f-addd-48271d9a06d7 --><!-- end item 63e08b77-43da-4a24-b50b-8d267c026301 -->","topic":{"id":"c96d68c3-bb0b-5b8c-b256-6b3e415d7ab2","topicId":"76763692-46bc-4f1e-add3-6c012ccd584a","topicName":"Pityriasis rosea","slug":"pityriasis-rosea","aliases":[],"chapters":[{"id":"82c04d82-7b6f-594a-8190-44f70c341f1b","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"0b21af5b-81ad-5b28-9df9-d6b7c4fdd3d4","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"357337fc-eefc-5ff8-84bf-cc4e15f9a2da","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"67565f4b-e371-5339-8d04-8fb65cb26c28","slug":"changes","fullItemName":"Changes"},{"id":"3b3d1372-8e27-5563-9a36-273677bd9a82","slug":"update","fullItemName":"Update"}]},{"id":"75f5c2f6-34b3-5b64-ab41-c7457b8eedd9","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"26135976-eb67-5dd8-ad15-9a98086871b7","slug":"goals","fullItemName":"Goals"},{"id":"96f6df37-1ba4-5020-8435-cbeac8de1488","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"026de696-4951-5e10-a246-456d67c1fea8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"03d26d2a-90f8-53c5-97e9-cff9d95ae299","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"87a8200e-6cd0-588d-8d4b-86117be364e6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ba1ef82b-8a8a-558d-a84a-552083dcd2e1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a8f04415-38ec-5eb9-8282-733c37db5bac","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"38f858f2-48f8-54e6-bb01-5b58106435cc","slug":"definition","fullItemName":"Definition"},{"id":"f7fffe58-e2a4-5913-8a5a-354aad8d52f0","slug":"causes","fullItemName":"Causes"},{"id":"090f1bfe-2513-53a8-ade3-e8368ec7d5d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"20025f23-bbb9-5095-9acc-da8d9e15840b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"72d63a33-0ca6-552f-81a8-200eef91d046","slug":"complications","fullItemName":"Complications"}]},{"id":"75dd0d1f-b162-54b6-b1ba-3833b13ae73e","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"44c5742e-2d6e-5ce6-806a-03940c5572f8","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f2c8da26-1065-5bb2-add8-43b39f41b5fe","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d71093b6-b130-5eeb-8e0f-443adf8be4aa","slug":"management","fullItemName":"Management","subChapters":[{"id":"0bc06d9c-42f1-5228-adf5-4eda9826e67a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c48f4302-0f7c-58d9-86ad-d5379d244e71","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"eee3f004-1425-502e-a455-287742b3ec77","slug":"emollients","fullItemName":"Emollients"},{"id":"51eb73bd-9e63-5028-815d-bf148fa863d9","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"186fab77-8c30-557b-bd7b-f756eb8f9cab","slug":"antihistamines","fullItemName":"Antihistamines"}]},{"id":"b3c2db78-1290-58fb-9bb3-3a5db8e45669","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"e683b047-2b38-5f72-a4b8-c79a83946894","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"2d6d1b8c-ffc1-59d1-89f5-a5abdf200635","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"27361c81-c185-5b67-b396-0305d0519609","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"45051d9e-ec60-5c2c-b5ba-3144fa01ed3b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4e570021-eea5-51d7-a0b9-52d2862efb98","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"259f8083-da67-544d-b6f7-dbb776d27e96","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4c25a2fe-3c87-5ac4-b4c3-7f8e41ff3c06","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"c96d68c3-bb0b-5b8c-b256-6b3e415d7ab2","topicId":"76763692-46bc-4f1e-add3-6c012ccd584a","topicName":"Pityriasis rosea","slug":"pityriasis-rosea","aliases":[],"topicSummary":"Pityriasis rosea is a skin rash that is characterized by distinctive scaly, erythematous lesions.","lastRevised":"Last revised in April 2020","nextPlannedReviewBy":"2025-04-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2025-03","nextPlannedReviewByDisplay":"March 2025","specialities":[{"id":"e174a859-759f-5b1d-898e-1a4155645e13","name":"Infections and infestations","slug":"infections-infestations"},{"id":"50071c38-ab10-5ab8-ac70-6bd19a96c24e","name":"Skin and nail","slug":"skin-nail"}],"chapters":[{"id":"82c04d82-7b6f-594a-8190-44f70c341f1b","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"0b21af5b-81ad-5b28-9df9-d6b7c4fdd3d4","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"357337fc-eefc-5ff8-84bf-cc4e15f9a2da","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"67565f4b-e371-5339-8d04-8fb65cb26c28","slug":"changes","fullItemName":"Changes"},{"id":"3b3d1372-8e27-5563-9a36-273677bd9a82","slug":"update","fullItemName":"Update"}]},{"id":"75f5c2f6-34b3-5b64-ab41-c7457b8eedd9","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"26135976-eb67-5dd8-ad15-9a98086871b7","slug":"goals","fullItemName":"Goals"},{"id":"96f6df37-1ba4-5020-8435-cbeac8de1488","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"026de696-4951-5e10-a246-456d67c1fea8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"03d26d2a-90f8-53c5-97e9-cff9d95ae299","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"87a8200e-6cd0-588d-8d4b-86117be364e6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ba1ef82b-8a8a-558d-a84a-552083dcd2e1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a8f04415-38ec-5eb9-8282-733c37db5bac","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"38f858f2-48f8-54e6-bb01-5b58106435cc","slug":"definition","fullItemName":"Definition"},{"id":"f7fffe58-e2a4-5913-8a5a-354aad8d52f0","slug":"causes","fullItemName":"Causes"},{"id":"090f1bfe-2513-53a8-ade3-e8368ec7d5d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"20025f23-bbb9-5095-9acc-da8d9e15840b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"72d63a33-0ca6-552f-81a8-200eef91d046","slug":"complications","fullItemName":"Complications"}]},{"id":"75dd0d1f-b162-54b6-b1ba-3833b13ae73e","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"44c5742e-2d6e-5ce6-806a-03940c5572f8","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f2c8da26-1065-5bb2-add8-43b39f41b5fe","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d71093b6-b130-5eeb-8e0f-443adf8be4aa","slug":"management","fullItemName":"Management","subChapters":[{"id":"0bc06d9c-42f1-5228-adf5-4eda9826e67a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c48f4302-0f7c-58d9-86ad-d5379d244e71","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"eee3f004-1425-502e-a455-287742b3ec77","slug":"emollients","fullItemName":"Emollients"},{"id":"51eb73bd-9e63-5028-815d-bf148fa863d9","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"186fab77-8c30-557b-bd7b-f756eb8f9cab","slug":"antihistamines","fullItemName":"Antihistamines"}]},{"id":"b3c2db78-1290-58fb-9bb3-3a5db8e45669","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"e683b047-2b38-5f72-a4b8-c79a83946894","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"2d6d1b8c-ffc1-59d1-89f5-a5abdf200635","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"27361c81-c185-5b67-b396-0305d0519609","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"45051d9e-ec60-5c2c-b5ba-3144fa01ed3b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4e570021-eea5-51d7-a0b9-52d2862efb98","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"259f8083-da67-544d-b6f7-dbb776d27e96","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4c25a2fe-3c87-5ac4-b4c3-7f8e41ff3c06","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"c96d68c3-bb0b-5b8c-b256-6b3e415d7ab2"}},"staticQueryHashes":["3666801979"]}